Menu
Search
|

Menu

Close
X

Five Prime Therapeutics Inc FPRX.OQ (NASDAQ Stock Exchange Global Select Market)

5.59 USD
+0.00 (+0.00%)
As of Jul 19
Previous Close 5.59
Open 5.58
Volume 83,446
3m Avg Volume 137,277
Today’s High 5.65
Today’s Low 5.49
52 Week High 17.34
52 Week Low 5.35
Shares Outstanding (mil) 36.06
Market Capitalization (mil) 201.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.10 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
5
FY18
50
FY17
40
FY16
31
EPS (USD)
FY19
-1.017
FY18
-4.109
FY17
-5.377
FY16
-2.431
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
8.87
7.97
Price to Book (MRQ)
vs sector
0.83
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.58
Return on Investment (TTM)
vs sector
-45.24
12.69
Return on Equity (TTM)
vs sector
-52.11
17.17

EXECUTIVE LEADERSHIP

William Ringo
Lead Independent Chairman of the Board, Since 2019
Salary: --
Bonus: --
Aron Knickerbocker
President, Chief Executive Officer, Chief Operating Officer, Director, Since 2018
Salary: $500,000.00
Bonus: --
David Smith
Chief Financial Officer, Executive Vice President, Principal Financial Officer, Since 2019
Salary: $44,103.00
Bonus: --
Helen Collins
Senior Vice President and Chief Medical Officer, Since 2017
Salary: $435,000.00
Bonus: --
David White
Principal Accounting Officer, Vice President - Finance, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

111 Oyster Point Blvd
SOUTH SAN FRANCISCO   CA   94080-1910

Phone: +1415.3655600

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

SPONSORED STORIES